FACULTY
Overcoming Life-Threatening Bacterial And Fungal Infections: Case-Based Discussions And Evidence-Based Strategies
Including proceedings from a satellite symposium held in conjunction with the Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting in Washington, DC
Activity Date: June 2006  — Activity Info: Volume 6, (6C)
Goals & Objectives | Faculty | Introduction | Full Activity Content | CME Test & Evaluation (CME Expired) | Order Copy of Activity

 

Full Disclosure Policy Affecting CME Activities:
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Program Directors and Participating Faculty reported the following:

PROGRAM DIRECTORS

John G. Bartlett, MD
Professor, Department of Medicine
Chief, Division of Infectious Diseases
Johns Hopkins University School of  Medicine
Baltimore, Maryland
Dr Bartlett reports serving as a consultant for Abbott Laboratories, Bristol-Myers Squibb Company, GlaxoSmithKline, and the HIV Advisory Board.

John R. Graybill, MD
Professor, Department of Medicine
Chief, Division of Infectious Diseases
University of Texas Health Science Center
San Antonio, Texas
Dr Graybill reports receiving grants/research support from Astellas, Merck and Company, Pfizer Inc, Schering-Plough, and Vicuron; serving as a consultant for Merck and Company, Pfizer Inc, and Schering-Plough; and receiving honoraria from Merck and Company and Schering-Plough.

PARTICIPATING FACULTY

Donald E. Craven, MD
Professor of Medicine
Tufts University School of Medicine
Chair, Infectious Diseases
Lahey Clinic Medical Center
Burlington, Massachusetts
Dr Craven reports receiving grants/research support from Bard; serving as a consultant for Johnson & Johnson; and receiving honoraria from Cubist Pharmaceuticals, Elan, Merck and Company, Pfizer Inc, and Wyeth.

George H. Karam, MD
Paula Garvey Manship Professor of Medicine
Louisiana State University School of Medicine
New Orleans, Louisiana
Dr Karam reports receiving honoraria from Merck and Company and Pfizer Inc.

John Perfect, MD
Professor of Medicine
Division of Infectious Diseases
Duke University
Durham, North Carolina
Dr Perfect reports receiving grants/research support from Astellas, Enzon, Merck and Company, Pfizer Inc, and Schering-Plough; serving as a consultant for Astellas, Enzon, Merck and Company, Pfizer Inc, and Schering-Plough; and receiving honoraria from Astellas, Enzon, Merck and Company, Pfizer Inc, and Schering-Plough.

Jack D. Sobel, MD
Professor and Division Chief
Infectious Diseases
Wayne State University School of Medicine
Detroit, Michigan
Dr Sobel reports receiving grants/research support from Astellas and Merck and Company; serving as a consultant for 3M Pharmaceuticals, Merck and Company, and Pfizer Inc; and receiving honoraria from 3M Pharmaceuticals, Merck and Company, Pfizer Inc, and Schering-Plough.

James S. Tan, MD, MACP, FCCP
Professor and Vice Chairman of Internal Medicine
Head, Infectious Disease Section
Northeastern Ohio Universities College of Medicine
Chairman, Department of Medicine
Summa Health System
Akron, Ohio
Dr Tan reports receiving honoraria from Aventis, Pfizer Inc, and Wyeth.

John Wingard, MD
Professor of Medicine
Department of Medicine
Director, Blood and Bone Marrow Transplant Program
University of Florida
Shands Cancer Center
Division of Hematology/Oncology
Gainesville, Florida
Dr Wingard reports receiving grants/research support from Merck and Company and Pfizer Inc; serving as a consultant for Merck and Company, Pfizer Inc, Schering-Plough, and Vical; receiving honoraria from Merck and Company and Pfizer Inc; serving as an investigator for Fujisawa and Ortho-McNeil; and serving on the speakerÕs bureau for Merck and Company and Pfizer Inc.

Notice: The audience is advised that articles in this CE activity contain reference(s) to unlabeled or unapproved uses of drugs or devices.

Dr Graybill—aminocandin, anidulafungin, caspofungin, posaconazole, and micafungin.
Dr Perfect—antifungal drugs without specific indications.

All other faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs or devices.

Johns Hopkins Advanced Studies in Medicine provides disclosure information from contributing authors, lead presenters, and participating faculty. Johns Hopkins Advanced Studies in Medicine does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.

     
Home | Contact Us | View Account | Need Help?